MAUI CERVANTES: Open Payments
NPI 1033825997 · LIVE OAK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,971 in 143 payments from 18 companies in 2025. Trend: 2023 $1,753 · 2024 $2,570 · 2025 $2,971
Food & beverage: $2,872Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $665 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $424 |
| Janssen Biotech, Inc. | 20 | $389 |
| Madrigal Pharmaceuticals | 17 | $359 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $236 |
| PFIZER INC. | 9 | $142 |
| Novo Nordisk Inc | 2 | $124 |
| Celltrion USA Inc. | 5 | $114 |
| Ardelyx, Inc. | 5 | $113 |
| Gilead Sciences, Inc. | 5 | $99 |
Products named: TREMFYA, REZDIFFRA, RINVOQ, XIFAXAN, ENTYVIO, MAVYRET, Wegovy, VEGZELMA.
Industry payments across TX — which companies pay providers there.
